Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 12/20 | 0.52 |
| ▸ | NPC1 | O15118 | 11/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31665327 | 0.86 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2949867 | 0.80 | SMN1; SMN2 (0.62) | GCKRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL30339219 | 0.78 | NPC1 (0.62) | GCKRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL24073804 | 0.78 | NPC1 (0.62) | GCKRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL23287061 | 0.77 | MAPK14 (0.43) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL31665552 | 0.76 | RAB9A (0.55) | GCKRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4290502 | 0.75 | SMN1; SMN2 (0.71) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL31110024 | 0.75 | SMN1; SMN2 (0.56) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL25142712 | 0.74 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4860081 | 0.74 | KMT2A (0.62) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | GCK 3820/4885RAB9A 2408/4885NPC1 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.